Indivior Pharmaceuticals (INDV) Total Debt (2021 - 2026)

Indivior Pharmaceuticals' Total Debt history runs 6 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• In Q1 2026, Total Debt rose 47.72% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (up 47.72% YoY), while the FY2025 annual figure was $319.0 million, down 4.2% from the prior year.
• Total Debt was $486.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $319.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $486.0 million in Q1 2026 to a low of $240.0 million in Q4 2022.
• Historically, Total Debt has averaged $324.4 million across 5 years, with a median of $324.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Debt declined 4.2% in 2025, then soared 47.72% in 2026.
• A 5-year view of Total Debt shows it stood at $240.0 million in 2022, then changed by 0.0% to $240.0 million in 2023, then jumped by 38.75% to $333.0 million in 2024, then declined by 4.2% to $319.0 million in 2025, then soared by 52.35% to $486.0 million in 2026.
• The last three Total Debt figures came in at $486.0 million (Q1 2026), $319.0 million (Q4 2025), and $322.0 million (Q3 2025), per Business Quant data.